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Cystic ﬁbrosis (CF) is an autosomal recessive disorder which despite advances in medical care continues to be a life-limiting and
often fatal disease. With increase in life expectancy of the CF population, bone disease has emerged as a common complication.
Unlike the osteoporosis seen in postmenopausal population, bone disease in CF begins at a young age and is associated with
signiﬁcant morbidity due to fractures, kyphosis, increased pain, and decreased lung function. The maintenance of bone health
is essential for the CF population during their lives to prevent pain and fractures but also as they approach lung transplantation
since severe bone disease can lead to exclusion from lung transplantation. Early recognition, prevention, and treatment are key
to maintaining optimal bone health in CF patients and often require a multidisciplinary approach. This article will review the
pathophysiology, current clinical practice guidelines, and potential future therapies for treating CF-related bone disease.
1.Introduction
Cystic ﬁbrosis (CF) is an autosomal recessive disorder caused
by defects in the cystic ﬁbrosis transmembrane conductance
regulator protein (CFTR), a chloride channel found in the
epithelial tissues in the lungs, sinuses, pancreas, skin, and
gastrointestinal tract. CF most commonly aﬀects Caucasians
and occurs with a frequency of 1 in 2000 to 3000 live births
in the United States each year [1]. The defects in CFTR leads
to alterations in the sodium, chloride, and water transport
in the epithelial cells and in turn to changes in the viscosity
and hydration of the ﬂuids overlying the epithelial cells. The
change in the ﬂuid composition is partially responsible for
several of the complications associated with the progression
of CF such as chronic respiratory infections, pancreatic duct
obstruction, pancreatic insuﬃciency, biliary obstruction,
cirrhosis as well as distal intestinal obstruction syndrome.
In addition to expression of CFTR in a variety of epithelial
cells, its expression has been found in osteoblasts but its
precise role in these cells remains to be elucidated [2, 3]. The
respiratory disease is hallmarked by bronchiectasis caused
by cycles of infection, inﬂammation, and destruction of the
airways. Airway clearance and aerosolized therapies have
beenastaplein thecareoftheCFpatients forthepastseveral
decades and have lead to an improvement in the lifespan of
the patients leading some to consider it now a life-limiting
instead of a fatal disease. However, CF continues to lead to
premature respiratory failure from repeated exacerbations,
chronic infection by Pseudomonas aeruginosa, Staphylococcus
aureus, Burkholderia cepacia, or other pathogenic organisms.
The rapid advancements in medical therapy and patient
care discussed above have increased the median pre-
dicted survival age for patients with CF to 37.4 years
(http://www.cﬀ.org/). In the coming years, the number of
patients with CF whoare over the age of 18 will surpass those
who are in the pediatric age group; currently approximately
forty-six percent of the CF population in the United States
is over 18 years of age. As a consequence, the various
disease-related complications that were only seen in a sub-
set of the CF population are now being seen in a larger
number of patients, such as osteoporosis and osteopenia.
The secondary bone loss seen in the CF population is
multifactorial, however can cause signiﬁcant morbidity in
the adult population.2 Journal of Osteoporosis
2.Bone Disease inCF
Bone disease in patients with cystic ﬁbrosis was ﬁrst
described over 3 decades ago and is characterized by
decreased mineral density, increased fracture rates, and
kyphosis [4, 5]. Unlike bone loss seen in postmenopausal
women, bone loss in the CF population begins at a young
ageand continues as the patient ages. The prevalence of bone
disease in the CF population increases with age and has been
correlated with severity of lung disease [6–11]. However, one
is more likely to see an adult CF patient with low bone
mineral density than with normal bone mineral density even
with normal lung function.
A recent meta-analysis by Paccou et al. reported that the
prevalence of osteoporosis and osteopenia in young adults
with CF was 23.5% and 38%, respectively [12]. Multiple
cross-sectional studies have demonstrated an increased inci-
dence of fractures in individuals with CF with vertebral
fractures being the most common followed by rib fractures
[4, 5, 13–15]. Another common skeletal problem seen in
the CF population seen as early as the third decade of
life is kyphosis [13, 16, 17]. Some studies have noted
it to be between 10%–40% CF patients [16, 17]. The
development of bone disease in the CF population can lead
to signiﬁcant issues with loss of lung function, deformities,
and also increased pain issues. One can imagine that a
vertebral or rib fracture would make it diﬃcult to maintain
a regimen of airway clearance that is needed for the
prevention of CF exacerbations and the maintenance of lung
function.
Although most of the pathologic consequences occur
during adulthood in the CF population, there have been
several studies that indicate that during childhood and
puberty the CF patients achieve approximately half of
the bone density than their healthy counterparts [18–22].
Puberty is especially important for the development of
bone density and is a time where there is both peak
growth velocity and bone density accrual. The reduction in
the bone formation in the CF patients may be due to a
combination of their delay in puberty, chronic infections,
and hormonal imbalances. Numerous cross-sectional and
longitudinal studies suggest that children and adolescents
with cystic ﬁbrosis fail to achieve adequate bone mass
as compared to healthy controls during their pubertal
growth spurt [18–20, 22] .T oc o m p o u n dt h i sd e c r e a s ei n
bone density in puberty and adolescence, clinical studies
show annualized rates of loss in BMD in the CF patients
approach those seen in postmenopausal women [23–25].
Lower baseline bone density coupled with increased losses
puts CF individuals at higher risk of low BMD.
The maintenance of bone health is also essential for
the CF population as they approach the time for lung
transplantation. Severe bone disease can lead to exclusion
from lung transplantation, which is often a life-saving
treatmentfor many CF patients. The most eﬀective strategies
have been found to be early recognition, prevention, and
treatment in this population. This article will discuss the
pathogenesis, the current guidelines, and potential therapies
for the CF population.
3. Pathogenesis
3.1. Histologically. Three of the studies that have looked at
bone histomorphometric data in CF adults with low BMD
have shown a decrease in cortical as well as trabecular
bone volume and a decrease in connectivity [26–28]. At a
cellular level, there is a disruption in the delicate balance
between osteoblast and osteoclast activities. The osteoblastic
activity is decreased in the bones of the CF patients due to
decreasedosteoblastnumberandtheirbiosyntheticpotential
that is compounded by osteoclast activity which is increased,
primarily through increased osteoclast number. The rise in
bone resorption when compared to new bone formation
leads to low bone density in this population even in
patients who are clinically stable [26, 28]. The exact cause
of the disruption in this balance has not been completely
been elucidated; however, there are studies to suggest that
mutations in CFTR itself may play a role in a portion of the
CF patients. Interestingly, even though vitamin D deﬁciency
is very common in individuals with CF and is an important
etiologic factor for the low BMD observed in this condition,
osteomalacia is usually not a feature of CF-related bone
disease [28].
4. Possible Role of CFTR
There are three observations that indicate that CFTR has a
direct association with the loss in bone density in the CF
patients. First, CFTR has been shown to be expressed in
human osteoblasts, osteocytes, and osteoclasts [3]. Second,
CF patients with at least one ΔF508 allele had signiﬁcantly
lower Z-scores than those with other genotypes, which
suggestsadirectassociationbetweenCF-relatedbonedisease
and the ΔF508 mutation [29]. Finally, experiments in CFTR-
deﬁcient mice demonstrated a decreased BMD with more
cortical bone thinning and altered trabecular architecture
as compared to control mice despite lacking other overt
manifestations of CF (e.g., lung disease and pancreatic
insuﬃciency) [30]. Together these ﬁndings suggest that
loss of CFTR function may adversely aﬀect bone density.
However, the exactrole ofCFTR, speciﬁcallytheΔF508 allele
in CF-related bone disease, is yet unclear.
In addition, the loss or reduction in CFTR activity has
been shown to lead to chronic inﬂammation through a
decrease in osteoprotegerin and a concomitant increase in
prostaglandin E2 [2]. The alteration of osteoprotegerin and
prostaglandin E2 increases the inﬂammation-driven bone
resorption [2]. This would further indicate that there is
a direct association between CFTR and the BMD in the
CF patients. These studies have increased the interest in
the possible role of CFTR gene in bone development and
pathophysiological processes. Once again however, it is not
known whether CFTR has a direct or indirect eﬀect on bone
formation.
5. FactorsInﬂuencingBone Loss
The development of bone disease in the CF patients is
thought also to be secondary to their chronic illness and isJournal of Osteoporosis 3
Table 1: Causes of decreased bone density in cystic ﬁbrosis.
(i) Pancreatic insuﬃciency
(ii) Malnutrition and poor growth
(iii) Vitamin D, vitamin K, and calcium insuﬃciency
(iv) CF-related diabetes
(v) Glucocorticoids
(vi) Sex steroid deﬁciency and delayed puberty
(vii) Chronic inﬂammation
(viii) Tobacco, alcohol, and caﬀeine use
(ix) Moderate to severe lung disease
(x) Lack of exercise, especially weight bearing
(xi) Organ transplant and immunosuppressive therapy
(xii) Medications (Depo-Provera, Megestrol Acetate, and
Aluminium containing-antiacids)
(xiii) Possible role of CFTR.
inﬂuenced by multiple factors. It is essential to remember
that nutrition, lung disease, and bone health are all related
in this population. (Table 1).
6. Malnutrition and Pancreatic Insufﬁciency
Optimum nutrition is vital not only for pulmonary health
butalsoforbonehealth[17,31–33].Malnutritionseeninthe
adult CF patients is contributed by pancreatic insuﬃciency,
increased catabolism due to chronic infections, and body
images issues which aﬄicts many of the CF patients. A
large portion of CF patients are pancreatic insuﬃcient
which leads to inadequate secretion of pancreatic enzymes
and malabsorption of fat soluble vitamins (A, D, E, and
K), calcium, and other macronutrients which play a key
role in bone formation [34]. Despite pancreatic enzyme
replacement therapy, the majority of CF patients have body
mass index that are in the low normal or malnutrition
range. A great deal of energy is spent on dietary education
and nutritional support in an attempt to improve the body
mass index of the CF population. Low body mass index has
been linked to low bone mineral density, especially in the
adolescent and young adults [35, 36].
6.1. Vitamin Deﬁciencies. One vitamin deﬁciency which is
prevalent in the CF population is Vitamin D deﬁciency,
regardless of season or latitude [37–40]. In addition to
pancreatic insuﬃciency and malabsorption described above,
multiple other factors such as inactivity and decreased
sunlight exposure, low body fat (reduced Vitamin D stores),
reduced 25 hydroxylation, increased metabolic degradation,
and decreased vitamin D binding protein have all been
implicated as potential etiologies for the low vitamin D
reserves.
In non-CF individuals, Vitamin D deﬁciency in children
results in failure to achieve optimal height and peak bone
mass or even overt rickets while in adults it is associated with
impaired bone density due to decreased calcium absorption
and hyperparathyroidism as well as osteomalacia. Although
Vitamin D deﬁciency is commonly seen in CF population,
osteomalacia in not a feature of CF-related bone disease,
suggesting that other etiologies play an equally important
role in pathogenesis [28].
Even with replacement therapy, vitamin K is known to be
depleted in up to 40% of the CF patients. The signiﬁcance
of vitamin K to bone health has been linked to osteocalcin.
A depletion of vitamin K has been associated with higher
levels of undercarboxylated osteocalcin. Several studies have
looked beneﬁcial role of vitamin K supplementation specif-
ically on the increased carboxylation of osteocalcin and
improvement in bone formation [38, 41–44].
7.CysticFibrosis-RelatedDiabetes
Patients with CF can develop impaired glucose tolerance
(IGT) or even frank diabetes due to the progressive pan-
creatic damage caused by defective acinar and ductular
secretions.Thistypeofpancreaticdamagemaynotbesimilar
to classic Type I or Type II diabetes; however, the resultant
abnormalities in glucose and insulin regulation can aﬀect
bone health [45–47]. Just as in patients without CF, cystic
ﬁbrosis-related diabetes and IGT may play an important role
in the development of bone loss [45].
8. GonadalSteroidDeﬁciency
Puberty is a crucial period in which peak bone mass accrual
occurs. CF individuals are frequently noted to have delayed
puberty and decreased overall bone mineral accretion.
Adolescents with CF have lower sex hormone levels as
compared to healthy age matched controls, but most have
normal values when adjusted for Tanner stage [48, 49].
Hypogonadism can cause accelerated bone loss. The lower
peak bone mass combined with increased bone losses may
contribute to bone disease, but observational studies have
not observed a consistent association [48, 49].
9.PhysicalInactivity
Just as with some of the general population, the CF
population is not as physically active as they should be.
Although there are limitations with many of the patients
with severe lung disease and there is social stigmata attached
to the chronic cough that the CF patients have especially
when exercising, any reduction in activity or weight bearing
activity in this population has negative impact on their
BMD. The CF patients are often burdened with a signiﬁcant
treatment burden and in the adult population frequent
pulmonary or sinus exacerbation. For all of these reasons,
there is a decrease in total activity hours and weight-bearing
activities in this population even in light of the fact that it4 Journal of Osteoporosis
has been shown not only to improve bone health but also
pulmonary health [32, 50–53].
10. RecurrentInfections
As stated previously, there is an association between the
severity of lung disease and CF-related bone disease [5–10].
During acute exacerbations of lung disease, markers of bone
turnover tend to rise and their levels drop after appropriate
treatment with antibiotics, chest physical therapy, improved
nutrition, and other supportive measures [54]. Systemic
hormones, inﬂammatory cytokines, and localized growth
factors can all aﬀect bone remodeling [55]. Elevated levels
of cytokines and growth factors like tumor necrosis factor-
α (TNF-α), vascular endothelial growth factor (VEGF) and
IL-1, IL-6 and IL-11 found in the serum and respiratory
tract of CF patients may stimulate osteoclast-mediated bone
resorption and inhibit bone formation [56].
11.Glucocorticoids
It is well established that glucocorticoids negatively impact
bone health. Their primary eﬀect on bone is to suppress
formation of osteoblasts and promote apoptosis of osteo-
clasts and osteocytes. Systemic glucocorticoids can cause a
rapid bone loss within the ﬁrst few months of treatment,
followed by a slower 2%–5% loss per year with chronic
use [57]. CF patients with symptoms and signs of asthma
or allergic bronchopulmonary aspergillosis are often treated
with systemic or oral steroids to improve lung function. In
most studies, the dose and duration of systemic steroid use
impacted the decreased bone mineral density [58–62]. The
useofinhaledcorticosteroids,althoughassociatedwithshort
term changes in markers of bone turnover, has not been
showntoaﬀectBMDorfracturerisk,independentofseverity
of underlying lung disease [58, 62].
12. LungTransplantationand
ImmunosuppressiveTherapy
Lung transplantation may be potentially lifesaving in CF
patients with end stage lung disease. Patients awaiting
lung transplants almost always have a low BMD due to
factors discussed above [63, 64]. Immediately following the
transplant, a rapid decline in BMD is noted and may be
attributed to limited mobility, chronic steroid use, and use
of other immunosuppressive agents [65–70]. This decreased
BMD is associated with an increased fracture risk. Though
BMD may stabilize or even increase a year or more after
transplant, the fracture risk appears unchanged [65].
13. Guidelinesto ImproveBone Health inCF
TheclinicalpracticeguidelineswereoutlinedbytheCFfoun-
dation committee for optimizing bone health in CF patients
in The Journal of Clinical Endocrinology & Metabolism in
2005 and are scheduled to be revised within the next year
[13].
13.1. Screening for Bone Disease. The CF foundation bone
health committee recommended that all adults with CF
should have a baseline BMD at age 18 years. Children age 8
yearsorgreaterwithotherrisk factors(i.e.,idealbody weight
<90%, FEV1 <50% predicted, glucocorticoids 5mg/day or
more for 90days/year or longer, delayed puberty, or previous
history of fractures) should also be screened.
The committee cautioned that while interpreting DEXA
scan results, Z-scores should be used up to age 18, Z-
or T-scores are nearly equivalent between ages 18 and 30,
while T-scores should be used above the age of 30. The
recommendations are summarized in Table 2.
13.2. Preventive Strategies. The preservation of optimal bone
health in CF requires a multisystemic approach. Good
nutrition is critical in maintaining lean body mass and
overall bone health. Vitamin and macronutrient deﬁciencies
should be adequately repleted, and a BMI >50% percentile
should be targeted. Pulmonary infections should be treated
aggressively, and every eﬀort should be made to maintain
adequate glycemic control and to minimize the use of
steroids whenever possible. Weight bearing exercises are well
known to increase BMD in healthy subjects and are highly
recommended in preventing bone loss in CF individuals.
14.TherapeuticConsiderations
14.1. Vitamin D Supplementation. As discussed previously,
Vitamin D insuﬃciency is common among CF patients
and is associated with bone disease. An optimum level has
not been established but based on observations in non-CF
patients that parathyroid hormone levels start to increase
w h e n2 5 O HV i tDl e v e l sf a l lb e l o w3 0 n g / m L ,t h eC F
foundation committee’s consensus guidelines recommend a
target 25OH Vit D level of 30ng/mL or 75nmol/L. It should
also be noted that the recommended daily allowance of Vit
D for non-CF individuals will not be adequate to maintain
target levels in CF patients. Various possible replacement
strategies have been suggested, but the optimal Vitamin D
analog and dose (D2, D3, calcifediol, calcitriol, and UV
therapy) remains to be determined.
14.2. Calcium Supplementation. Calcium is an important
component of bone infrastructure and is essential to the
maintenance of skeletal health. Schulze et al. showed that
increased calcium absorption in young women with CF was
associated with increased rates of bone calcium deposition
[34]. Since there are no long-term randomized controlled
trials in CF patients, appropriate supplemental doses are
not deﬁned and national dietary reference intakes should
be followed. The CF foundation bone health consensus
committee recommends supplementation with 1300mg to
1500mg of elemental calcium daily.
14.3. Vitamin K Supplementation. Vitamin K is necessary for
posttranslational activation of osteocalcin, which in turn is
important for bone formation and mineralization [42, 43].Journal of Osteoporosis 5
Table 2: Cystic ﬁbrosis foundation guidelines for treatment of osteoporosis.
General Recommendations
Vitamin D goal 25OH Vit D level >75nmol/L or 30ng/mL
Calcium 1300–1500mg/day
Vitamin K 0.3–0.5 mg/day
Target BMI
>50th percentile
BMI adult females 23
BMI adult males 22
Exercise Encourage outdoor and weight bearing exercise
Infections Aggressive treatment of pulmonary infections
Speciﬁc Recommendations by T/ZScore
T/Zscore ≤− 2 −1≤T/Zscore ≤− 2T / Z s c o r e s ≥− 1.0
Repeat DEXA Annual Repeated every 2–4 years Repeated every 5 years
Steroid Minimize steroid doses No recommendation
Endocrine Recognize and treat CF related diabetes, delayed puberty, hypogonadism, and
consider endocrine consult No recommendation
Bisphosphonate Start bisphosphonate
If fragility fracture, patient awaiting
transplant or accelerated BMD loss
>3-5% per year start bisphosphonate
No recommendation
Clinical practice guidelines recommend supplementation
w i t h0 . 3t o0 . 5m gd a i l y .
14.4. Gonadal Steroid Replacement Therapy. While adoles-
cents with CF have lower sex hormone levels as compared to
healthyagematchedcontrols,mosthavenormalvalueswhen
adjusted for Tanner stage [48, 49]. The risk/beneﬁt ratio of
sex steroid replacement has not been adequately studied.
Gonadal hormone replacement is controversial and should
be limited only to those patients who have persistently low
levels [13, 71]. Delayed puberty should be addressed by an
experienced endocrinologist.
14.5. Antiresorptive Agents. Bisphosphonates are a class of
drugs that chemically bind to calcium hydroxyl-apatite in
bone and inhibit bone resorption through their inhibitory
action on osteoclasts function and survival. Observational
and randomized controlled trials (RCTs) on adults with
CF have shown signiﬁcant improvement in BMD with
IV pamidronate and IV zoledronic acid as well as PO
alendronate, but trials of these drugs in children with CF
have not been performed [23–25, 65, 72, 73]. Oral agents
are currently considered the ﬁrst-line therapy for CF-related
bone disease. The IV agents are frequently associated with
side eﬀects like fever, severe body aches, and bone pains
[25,65,72],butconcomitantuseofsteroids,acetaminophen,
and/or nonsteroidals may help reduce this pain and fever
syndrome.
The current guidelines strongly recommend consider-
ation of bisphosphonate therapy in all CF patients with
T/Z-scores less than −2.0 and also in patients with T/Z
score between −1.0 and −2.0, with a history of fragility
fractures, those awaiting lung transplant, or who experience
a BMD loss of >3%–5% per year. It is essential that when a
bisphosphonate is used that the Vitamin D and calcium are
adequately replaced prior to and during therapy.
14.6. Recombinant Human Growth Hormone. Children with
CF are noted to have poor linear growth and inadequate
weight gain as well as low levels of IGF-1. The use of growth
hormone in children with CF has been shown to have a
beneﬁcial eﬀect on linear growth and weight gain. There is
evidence to suggest that treatment with recombinant human
growth hormone results in improvement in clinical status
with decreased hospitalizations and courses of intravenous
antibiotics, improvement in exercise tolerance, and bone
accumulation [74–79]. Human recombinant growth hor-
mone has not been studied as a treatment for low BMD in
adults with cystic ﬁbrosis [74, 75, 77, 78, 80].
14.7. Teriparatide. Human parathyroid hormone has been
shown to have both anabolic and catabolic eﬀects on
bone, depending on the dose and duration of use. While
continuous exposure to high doses leads to bone resorption,
daily low dose injections may actually increase osteoblast
formation and bone growth [81–84]. Teriparatide (PTH 1–
34) is the only anabolic agent available in the US for use in
patientswithadvancedosteoporosisathighriskforfractures.
Recombinant human (PTH 1–84) is available in Europe.
It is contraindicated in children with open epiphyses but
holdspromiseforCFadultswithsevereosteoporosisorprior
history of fractures. There are currently no published studies6 Journal of Osteoporosis
of teriparatide in CF; however, this maybe a therapeutic
option that should be considered and studied in the future
for the adult population.
14.8. Newer Agents. Over the past few decades, researchers
have made signiﬁcant strides in the ﬁeld of osteoporosis,
which has led to an improved understanding of the regula-
tion of bone remodeling. Exciting new treatment strategies
have emerged and may potentially broaden our options for
treatmentofCF-relatedbonedisease.Severalofthetherapies
discussed are not clinically available currently but are under
investigation and show promise to improve the bone health
of the CF patients in the future.
14.8.1. Antiresorptive Agents. Denosumab, a human mono-
clonal antibody to RANKL (receptor activator of nuclear
factor kappaB ligand), was recently approved by FDA
for treatment of osteoporosis in postmenopausal women.
Denosumabinhibitsthematurationofosteoclastsbybinding
to RANKL [85]. The inhibition of osteoclast formation,
function, and survival are responsible for decrease in
osteoclast-mediated bone resorption. The improvement in
lumbar and hip BMD seen with denosumab is at least
comparable to bisphosphonates, if not superior. Denosumab
also improves distal radius (cortical) bone density, an eﬀect
not seen with bisphosphonates [85]. Side eﬀects noted
with bisphosphonates such as delayed fracture healing,
osteonecrosis of jaw, and femoral shaft fractures have not
been observed in denosumab-treated individuals to date
but further trials would be needed to assess the long-term
eﬀects of this medication [85]. The beneﬁcial eﬀect on both
trabecular as well as cortical bone, combined with fewer side
eﬀects and the prospect of improved patient compliance due
to twice-yearly dosing makes this an attractive consideration
in CF-related bone disease.
Cathepsins areafamilyofproteaseswithcollagenastheir
main target. Cathepsin K (CAT k) is unique to osteoclasts
and plays a role in degradation of bone matrix proteins,
including collagen. CATk inhibitors have an antiresorptive
eﬀect, with lesser inhibition of bone formation than bis-
phosphonates. CATk inhibitors have been shown in animal
studies to increase cortical thickness and periosteal bone
formation and are currently undergoing phase 3 trials. They
may have the potential to improve long bone strength and
prevent nonvertebral fractures [86, 87].
14.8.2. Anabolic Agents
PTH ligands and PTHrP. Antiresorptive agents can only
increase bone mass but anabolic agents can also improve
bone quality and strength, in addition to increasing bone
mass. Currently, PTH [1–34] is the only approved anabolic
agent in the US, and its duration of use is limited for 2
years. There is thus an unmet need for development of more
anabolic agents.
Researchers have looked at various PTH ligands (PTH
1–31, PTH 1–28), which appear to have a more potent
anabolic eﬀect than the hormone itself (PTH 1–34) [88, 89].
Parathyroid hormone-related protein (PTHrP) is a hormone
produced by mature osteoblasts and is structurally similar
to PTH. Unlike PTH, which has both anabolic and catabolic
eﬀects on bone, PTHrP appears to be purely anabolic when
administered intermittently. Studies in animals have shown
an increase in trabecular bone volume, osteoblast number,
bone mineralization rates, biomechanical strength, and
BMD [90]. Human studies show increase in BMD similar
to that with PTH, but without signiﬁcant hypercalcemia
or other adverse eﬀects as observed with PTH. There is
no activation of bone resorption at therapeutically eﬀective
doses [91–93].
14.8.3. Calcilytic Agents. Allosteric modulations of the G-
protein coupled calcium-sensing receptor in the parathyroid
gland can aﬀect PTH release. Positive allosteric modula-
tors decrease PTH production, while negative modulators
increaseit.Calcilyticsorcalciumsensingchannelantagonists
are negative modulators, which when administered orally,
can cause a pulsatile increase in PTH production. Animal
studies look promising; unfortunately, a human trial of
ronacaleret was discontinued due to a poor eﬀect on BMD.
Another agent is currently in phase 2 trials [94].
14.8.4. Modulation of the Wnt Signaling Pathway
Antisclerostin Antibody. A large family of extracellular gly-
coproteins, called Wnt proteins, are key regulators of bone
remodeling and other cellular processes [95–97]. Scleros-
teosis, an autosomal recessive disorder characterized by
increased bone mass, mainly in the skull and in long bones,
results from a mutation in the SOST gene, which codes for
sclerostin [98]. A deﬁciency of sclerostin results in increased
Wnt signaling and high bone mass. Transgenic mice that
overexpress sclerostin are seen to have low bone mass and
increased susceptibility to fractures [99] while mice deﬁcient
in sclerostin show increased bone density [100]. Treatment
with sclerostin antibody has been associated with an increase
in bone mass and strength in various animal models [101–
103].InaphaseItrialin72healthymenandpostmenopausal
women, a single subcutaneous dose of sclerostin antibody
was associated with a statistically signiﬁcant increase in
the levels of bone formation markers propeptide of type I
procollagen (P1NP), osteocalcin and bone-speciﬁc alkaline
phosphatase (BSAP), a dose-dependent decrease in bone
resorption marker C-telopeptide, and a 5.3% increase in
lumbar spine BMD [104]. Antisclerostin antibody seems
promising as a potentially eﬀective anabolic agent for the
treatment of low bone mass in individuals with CF.
Anti-Dkk1 Antibody. Dickoppf1 (DKK1) is a naturally
occurring Wnt pathway antagonist which works by pre-
venting the interaction between two key Wnt pathway
coreceptors, LRP5/6 and the frizzled Wnt pathway receptor,
which results in inhibition of Wnt signal transduction and
impaired bone formation [105]. DKK1 inhibition increases
trabecular bone volume and bone formation in rats [106,
107]. Antibodies to dickkopf-1 could be used as an anabolic
agent for the treatment of patients with low bone mass.Journal of Osteoporosis 7
Activin Inhibitors. Activin is a member of the bone morp-
hogenic protein (BMP)/transforming growth factor (TGF)β
superfamily of polypeptides and stimulates the release of
FSH by the pituitary gland [108]. In bone, activin binds
to activin receptor IIA, increases osteoclastogenesis, and
is a negative regulator of bone mass. Its eﬀects on bone
formation are more complex and unclear [109].
ACE-011, a protein formed by fusing soluble activin
receptor type II to IgG-Fc, was shown to decreases bone
resorption in ovariectomized mice and enhance bone forma-
tion in intact animals [110]. Data in cynomolgus monkeys
shows a signiﬁcantly higher BMD and trabecular bone
volumeafterinjectionofACE-011[111].InphaseItrials,the
administrationofasingledoseto48postmenopausalwomen
resulted in an increase in levels of bone-speciﬁc alkaline
phosphatase and a decrease in C-telopeptides [112]. Activin
inhibitors hold promise as new anabolic therapy for patients
withlowbonemassandincreasedsusceptibilityforfractures.
15. Conclusion
CF-related bone disease is a common complication in the
aging CF population. It is multifactorial in origin, aﬀects
young individuals, and is associated with signiﬁcant mor-
bidity. Despite increasing research in the ﬁeld, numerous
questions about pathogenesis and appropriate therapy still
remain. A multisystemic, multidisciplinary approach is req-
uired to tackle bone disease in the CF population. Various
therapies are currently available for treatment of post-
menopausal osteoporosis but these have not been studied in
individuals with CF. Clinical trial data is especially limited in
the pediatric age group. The new Cystic Fibrosis Foundation
guidelines for the treatment of bone disease are expected
to be published in the next year. Exciting new therapies are
currently under development, and investigation and hold
promise for reducing the burden of secondary bone disease
in individuals with CF.
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